TFF Pharmaceuticals Partners With Emory University, BARDA to Powderize Antiviral Drug

MT Newswires Live09-11

TFF Pharmaceuticals (TFFP) said Wednesday that it has partnered with Emory University and the US Biomedical Advanced Research and Development Authority, or BARDA, to test the possibility of converting Emory's antiviral against influenza and COVID into a dry powder for inhalation.

Financial terms were not disclosed.

TFF said the contract supports early-stage therapeutic platform development under BARDA's Flexible and Strategic Therapeutic program.

The company said powderizing the mRNA-based treatment improves the stability of the drug and eliminates the need for cold-chain storage.

Price: 1.9400, Change: -0.06, Percent Change: -3.00

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466628802?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-11 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466628802","market":"fut","top_or_hot":-1,"title":"TFF Pharmaceuticals Partners With Emory University, BARDA to Powderize Antiviral Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a> (TFFP) said Wednesday that it has partnered with Emory University and the US Biomedical Advanced Research and Development Authority, or BARDA, to test the possibility of converting Emory's antiviral against influenza and COVID into a dry powder for inhalation.</p><p>Financial terms were not disclosed.</p><p>TFF said the contract supports early-stage therapeutic platform development under BARDA's Flexible and Strategic Therapeutic program.</p><p>The company said powderizing the mRNA-based treatment improves the stability of the drug and eliminates the need for cold-chain storage.</p><p>Price: 1.9400, Change: -0.06, Percent Change: -3.00</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TFF Pharmaceuticals Partners With Emory University, BARDA to Powderize Antiviral Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTFF Pharmaceuticals Partners With Emory University, BARDA to Powderize Antiviral Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-11 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TFF Pharmaceuticals (TFFP) said Wednesday that it has partnered with Emory University and the US Biomedical Advanced Research and Development Authority, or BARDA, to test the possibility of converting...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466628802","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466628802","pubTimestamp":1726056320,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TFF Pharmaceuticals (TFFP) said Wednesday that it has partnered with Emory University and the US Biomedical Advanced Research and Development Authority, or BARDA, to test the possibility of converting","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TFFP":"TFF Pharmaceuticals"},"translate_title":"TFF Pharmaceuticals与埃默里大学、BARDA合作开发粉状抗病毒药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TFFP":1},"content_text":"TFF Pharmaceuticals (TFFP) said Wednesday that it has partnered with Emory University and the US Biomedical Advanced Research and Development Authority, or BARDA, to test the possibility of converting Emory's antiviral against influenza and COVID into a dry powder for inhalation.Financial terms were not disclosed.TFF said the contract supports early-stage therapeutic platform development under BARDA's Flexible and Strategic Therapeutic program.The company said powderizing the mRNA-based treatment improves the stability of the drug and eliminates the need for cold-chain storage.Price: 1.9400, Change: -0.06, Percent Change: -3.00","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466628802"}